Cybin Inc., a leading biopharmaceutical company, has recently completed the dosing phase of its groundbreaking Phase 2 study for CYB003, a revolutionary deuterated psilocybin analog program aimed at combatting major depressive disorder (MDD). This study, consisting of six cohorts, examined various doses ranging from 1mg to 16mg. Remarkably, CYB003 has proven to be safe and well-tolerated at all evaluated doses, with no serious adverse events or discontinuations due to adverse events observed in the final dose cohort.
Excitingly, the primary efficacy endpoint of the Phase 2 study has been successfully achieved, as improvements in depression symptoms were noticed after just a single dose of CYB003. As we eagerly await the fourth quarter of 2023, Cybin Inc. is preparing to present its topline efficacy data, which will play a vital role in shaping their future plans for pivotal studies. Additionally, an optional period of assessment will be conducted to determine the long-lasting effects of the treatment, extending up to 12 weeks.
CYB003, the deuterated psilocybin analog, holds immense promise in effectively treating not only MDD but also alcohol use disorder (AUD). Its unique design aims to provide rapid onset and short duration of effect, minimal variability in plasma levels, efficacy at low doses, and potentially faster and sustained therapeutic outcomes compared to existing treatments. The psychedelic effects exhibited by CYB003 further indicate its potential in addressing MDD and AUD, offering hope for those in need of innovative solutions.
Updated on: 03/03/2024
Debt to equity ratio: Sell
Price to earnings ratio: Sell
Price to book ratio: Buy
ROE: Strong Sell
We did not find social sentiment data for this stock
There are no analysts data to display
CYBN Stock Analysis: Volatile Performance and Future Prospects of CYBIN Inc.
CYBN (CYBIN Inc.) is a health technology company operating in the pharmaceuticals industry. On October 31, 2023, CYBN stock had a previous close of $0.61 and opened at $0.67. Throughout the day, the stock’s price fluctuated within a range of $0.62 to $0.74. The trading volume for the day was 15,915,318 shares, significantly higher than the average volume of 4,068,450 shares over the past three months.
The market capitalization of CYBN stands at $195.4 million, indicating the company’s overall value in the stock market. In terms of earnings growth, CYBN experienced a positive growth rate of 39.95% in the previous year.
The P/E ratio for CYBN is not provided, denoted as “NM” (not meaningful). This could be due to negative earnings or lack of available data. The price/sales ratio and net profit margin are also not provided. However, the price/book ratio is reported as 3.48, indicating that the stock is trading at a multiple of 3.48 times its book value.
CYBN is headquartered in Toronto, Ontario, and operates in the health technology sector. The company specializes in pharmaceuticals, particularly in the major pharmaceuticals segment.
Looking ahead, CYBN’s next reporting date is scheduled for November 29, 2023. The earnings per share forecast for the current quarter is -$0.04, indicating a potential loss. In terms of annual financials, CYBN reported zero revenue and a net loss of -$35.9 million in the previous year.
Overall, CYBN’s stock performance on October 31, 2023, showed some volatility with a higher trading volume than usual. However, without complete financial data and growth projections, it is challenging to assess the long-term prospects of the company. Investors should closely monitor future financial reports and announcements to make informed decisions regarding CYBN stock.
Promising Performances of CYBN Stock on October 31, 2023: Analysts Target Price, Earnings, and Sales Analysis
CYBN stock has shown promising performances on October 31, 2023, with a median target price of 4.50 according to four analysts. This represents a significant increase of 586.50% from the last recorded price of 0.66. The high estimate is 10.00, and the low estimate is 3.00. The current consensus among the four polled investment analysts is to buy stock in Cybin Inc. The current quarter earnings per share for CYBN is -$0.04, indicating a loss in earnings. Sales for the current quarter are reported at $0.00, which may imply a lack of revenue generation or a delayed reporting of sales figures. The upcoming reporting date of November 29 may provide further insights into the financial performance of Cybin Inc. Investors should conduct thorough research and consider their risk tolerance before making any investment decisions.